

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA Atogepant for preventing migraine

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Final draft guidance

(when no draft guidance was issued)

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

Yes. At scoping, it was highlighted that migraine is a disability under the Equality Act 2010, that migraine is more common in women and that there may be issues in accessing treatment and availability of specialist care. The committee agreed that issues relating to differences in prevalence or incidence of a condition cannot be addressed in a technology evaluation. The committee considered that atogepant could improve access to specialist treatment for people with difficulty self-injecting the CGRP monoclonal antibodies administered subcutaneously.
---

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

No additional equality issues were raised.
--

- |  |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

N/A

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

Yes, in section 3.14.

**Approved by Associate Director (name):** Jasdeep Hayre

**Date:** 19 March 2024